Research graph
References from Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV. Local targets link to admitted publications; unresolved targets remain external evidence.
HIV Persistence in the Setting of Antiretroviral Therapy: When, Where and How Does HIV Hide?
10.1016/s2055-6640(20)30490-8 · 2015 · External reference
The Paradox of HIV Blood–Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies
10.1016/j.tins.2020.06.007 · 2020 · External reference
Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy‐Experienced Human Immunodeficiency Virus‐1–Infected Adults in the United States
10.1093/cid/ciy267 · 2018 · External reference
Blood–Brain Barrier Integrity, Intrathecal Immunoactivation, and Neuronal Injury in HIV
2016 · External reference
SLC22A2 Variants and Dolutegravir Levels Correlate With Psychiatric Symptoms in Persons With HIV
10.1093/jac/dky508 · 2019 · External reference
Impact of UGT1A1 Gene Polymorphisms on Plasma Dolutegravir Trough Concentrations and Neuropsychiatric Adverse Events in Japanese Individuals Infected With HIV‐1
10.1186/s12879-017-2717-x · 2017 · External reference
Patient Experiences of Switching From Efavirenz‐ to Dolutegravir‐Based Antiretroviral Therapy: A Qualitative Study in Uganda
10.1186/s12879-021-06851-9 · 2021 · External reference
Comparative Efficacy, Tolerability and Safety of Dolutegravir and Efavirenz 400mg Among Antiretroviral Therapies for First‐Line HIV Treatment: A Systematic Literature Review and Network Meta‐Analysis
10.1016/j.eclinm.2020.100573 · 2020 · External reference
Neuropsychiatric Adverse Drug Reactions and Associated Factors in a Cohort of Individuals Starting Dolutegravir‐Based or Efavirenz‐Based Antiretroviral Therapy in Belo Horizonte, Brazil
10.1080/03007995.2023.2189855 · 2023 · External reference
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV‐1‐Infected, Antiretroviral Therapy‐Naive Subjects
10.1093/cid/ciu477 · 2014 · External reference
Metabolism, Excretion, and Mass Balance of the HIV‐1 Integrase Inhibitor Dolutegravir in Humans
10.1128/aac.00292-13 · 2013 · External reference
Dolutegravir Cerebrospinal Fluid Diffusion in HIV‐1–Infected Patients With Central Nervous System Impairment
10.1093/ofid/ofz174 · 2019 · External reference
Pharmacokinetic Approaches to Standardize Antiviral Exposure in Cerebrospinal Fluid
10.1002/phar.70013 · 2025 · External reference
Cognitive Performance, Neuropsychiatric Symptoms, and Cerebrospinal Fluid Viral Control Following Programmatic Switch From Efavirenz‐Based to Dolutegravir‐Based Antiretroviral Therapy in South Africa (CONNECT): A Prospective Cohort Study
10.1016/s2352-3018(24)00209-1 · 2024 · External reference
A Sensitive HPLC–MS/MS Method for the Determination of Dolutegravir in Human Plasma
10.1016/j.jchromb.2013.11.054 · 2014 · External reference
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered With Rifampicin
10.1128/aac.00215-22 · 2022 · External reference
Drug–Drug Interaction Between Rifabutin and Dolutegravir: A Population Pharmacokinetic Model
10.1111/bcp.15604 · 2023 · External reference
Population Pharmacokinetics of Dolutegravir in HIV‐Infected Treatment‐Naive Patients
10.1111/bcp.12639 · 2015 · External reference
Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics: Application to d ‐Tubocurarine
10.1002/cpt1979253358 · 1979 · External reference
Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis
10.1093/infdis/jiaf178 · 2025 · External reference
Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best‐Case Performance
10.1023/b:jopa.0000012998.04442.1f · 2003 · External reference
A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R
2016 · External reference
Effect of Obesity on Dolutegravir Exposure in Black Southern African Adults Living With HIV
10.4102/sajhivmed.v23i1.1452 · 2022 · External reference
10.1093/infdis/jiaf305
10.1093/infdis/jiaf305 · External reference
On the Rate and Extent of Drug Delivery to the Brain
10.1007/s11095-007-9502-2 · 2008 · External reference
In Vitro Antiretroviral Properties of S/GSK1349572, a Next‐Generation HIV Integrase Inhibitor
10.1128/aac.01209-10 · 2011 · External reference
HIV‐1‐RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen
10.1093/infdis/jiw406 · 2016 · External reference
Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV‐Negative Men After Single and Multiple Dosing
10.1097/qai.0b013e31829ed7a4 · 2013 · External reference
Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV‐Negative Women
10.3851/imp2665 · 2013 · External reference
Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester
10.3389/fped.2021.734122 · 2021 · External reference
Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50‐Percent Inhibitory Concentration for Wild‐Type HIV‐1
10.1128/aac.00507-10 · 2010 · External reference
10.1097/ftd.0000000000000618
10.1097/ftd.0000000000000618 · External reference
10.1002/jcph.2494
10.1002/jcph.2494 · External reference
Dolutegravir Pharmacokinetics in Ugandan Patients With TB and HIV Receiving Standard‐ Versus High‐Dose Rifampicin
10.1128/aac.00430-23 · 2023 · External reference
The Population Pharmacokinetics of Dolutegravir Co‐Administered With Rifampicin in Thai People Living With HIV : Assessment of Alternative Dosing Regimens
2025 · External reference
10.1093/jac/dkz217
10.1093/jac/dkz217 · External reference
Evaluation of the Effect of UGT1A1 Polymorphisms on Dolutegravir Pharmacokinetics
10.2217/pgs.13.190 · 2014 · External reference
